Olympus Partners reported on Wednesday the completion of the divestiture of The Ritedose Corporation for an undisclosed amount.
Ritedose, a leading manufacturer of respiratory and ophthalmic drugs, is the foremost pharmaceutical manufacturer utilising "blow-fill-seal" technology, where a container is formed, filled and sealed in a continuous, highly automated process inside a sterile enclosed machine in a "clean room" facility.
Since Ritedose's acquisition in 2009, the company has grown to the second largest generic respiratory player, launched its own generic pharmaceutical brand, increased production capacity by 80% and expanded into new therapeutic categories such as dry eye.
Founded in 1988, Olympus Partners is a private equity firm focused on providing equity capital for management buyouts and for companies needing capital for expansion.
In the sale, Ritedose was represented by William Blair and Robert W. Baird with legal representation from Kirkland & Ellis.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling